

Key questions

These questions relate to issues raised in the Seminar. Please submit your views on these and other relevant issues to us at www.2020health.org

1. UK Vaccination – Process

Bearing in mind the increasing number of vaccines being developed, and the importance of research to the UK knowledge economy, should the Research and Development Directorate budget be hypothecated?

Should JCVI meetings be more open to the public?

How could the process of public engagement with the JCVI be more transparent?

Would there be any advantages if the Joint Committee on Vaccination and Immunisation (JCVI) came under the umbrella of the National Institute of Clinical Excellence (NICE)?

2. UK vaccination - Accessibility

Should members of the UK public be permitted to buy licensed vaccines to protect themselves and their families, even if they are not recommended by the JCVI for national use?
Eg for chicken pox or rotavirus?

Who would take responsibility for publicising the availability of licensed but non-universal immunisations?

Should the elderly be able to access the conjugate pneumococcal vaccine?

Should boys be given the choice of receiving the HPV vaccine?

3. International - standards and costs of immunisation

Should immunisation policies be standardised across all countries in order to reduce transmission of infections resulting from unvaccinated travellers, and to facilitate easier recruitment of overseas workers?

How could this be achieved?

How can we incentivise the consideration of the needs of and benefits to developing countries by vaccine manufacturers?

4. International - Tackling pneumococcal diseases in African children

Given the lifesaving benefits of pneumococcal vaccination in children, but the prevalence of different serotypes, how can priority be given to establishing and financing appropriate manufacture and distribution programmes whilst acknowledging the financial risk?

How can governments be encouraged to invest in vaccination for public health?